These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 31114413)

  • 1. Cold agglutinin disease: current challenges and future prospects.
    Berentsen S; Röth A; Randen U; Jilma B; Tjønnfjord GE
    J Blood Med; 2019; 10():93-103. PubMed ID: 31114413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How I manage patients with cold agglutinin disease.
    Berentsen S
    Br J Haematol; 2018 May; 181(3):320-330. PubMed ID: 29363757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sutimlimab for the Treatment of Cold Agglutinin Disease.
    Berentsen S
    Hemasphere; 2023 May; 7(5):e879. PubMed ID: 37153870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Treatment Options in Cold Agglutinin Disease: B-Cell Directed or Complement Directed Therapy?
    Berentsen S; Tjønnfjord GE
    Transfus Med Rev; 2022 Oct; 36(4):181-187. PubMed ID: 36127205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?
    Berentsen S; Barcellini W; D'Sa S; Jilma B
    Immunotherapy; 2022 Oct; 14(15):1191-1204. PubMed ID: 35946351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cold agglutinin disease.
    Berentsen S
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):226-231. PubMed ID: 27913484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoimmune hemolytic anemia.
    Hill A; Hill QA
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):382-389. PubMed ID: 30504336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cold agglutinin-mediated autoimmune hemolytic anemia.
    Berentsen S; Randen U; Tjønnfjord GE
    Hematol Oncol Clin North Am; 2015 Jun; 29(3):455-71. PubMed ID: 26043385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement-directed therapy for cold agglutinin disease: sutimlimab.
    Broome CM
    Expert Rev Hematol; 2023; 16(7):479-494. PubMed ID: 37256550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies for treatment of cold agglutinin disease.
    Gelbenegger G; Berentsen S; Jilma B
    Expert Opin Biol Ther; 2023 May; 23(5):395-406. PubMed ID: 37128907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cold agglutinin disease: pathology, diagnosis, and treatment].
    Wada H
    Rinsho Ketsueki; 2024; 65(6):521-528. PubMed ID: 38960651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel insights into the treatment of complement-mediated hemolytic anemias.
    Berentsen S; Hill A; Hill QA; Tvedt THA; Michel M
    Ther Adv Hematol; 2019; 10():2040620719873321. PubMed ID: 31523413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sutimlimab: A Complement C1s Inhibitor for the Management of Cold Agglutinin Disease-Associated Hemolysis.
    Moore DC; Arnall JR
    Ann Pharmacother; 2023 Aug; 57(8):970-977. PubMed ID: 36476151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Stage 1.
    Barcellini W; Zaninoni A; Giannotta JA; Fattizzo B
    J Clin Med; 2020 Nov; 9(12):. PubMed ID: 33261023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia.
    Berentsen S
    Front Immunol; 2020; 11():590. PubMed ID: 32318071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program.
    Gelbenegger G; Schoergenhofer C; Derhaschnig U; Buchtele N; Sillaber C; Fillitz M; Schenk TM; D'Sa S; Cartwright R; Gilbert JC; Jilma B; Jaeger U
    Blood Adv; 2020 Mar; 4(6):997-1005. PubMed ID: 32176765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease.
    Barcellini W; Fattizzo B
    Expert Rev Hematol; 2024 Jul; 17(7):287-294. PubMed ID: 38872338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How I treat cold agglutinin disease.
    Berentsen S
    Blood; 2021 Mar; 137(10):1295-1303. PubMed ID: 33512410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial.
    Jäger U; D'Sa S; Schörgenhofer C; Bartko J; Derhaschnig U; Sillaber C; Jilma-Stohlawetz P; Fillitz M; Schenk T; Patou G; Panicker S; Parry GC; Gilbert JC; Jilma B
    Blood; 2019 Feb; 133(9):893-901. PubMed ID: 30559259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease.
    Röth A; Barcellini W; D'Sa S; Miyakawa Y; Broome CM; Michel M; Kuter DJ; Jilma B; Tvedt THA; Weitz IC; Yoo R; Jayawardene D; Vagge DS; Kralova K; Shafer F; Wardȩcki M; Lee M; Berentsen S
    Am J Hematol; 2023 Aug; 98(8):1246-1253. PubMed ID: 37246953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.